Previous studies have demonstrated the effectiveness of normalizing tumor vasculature in murine mammary carcinoma models using a vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibitor, resulting in improved vessel perfusion and therapeutic delivery to tumors, thereby enhancing tumor killing. Here, PTPRB is linked to neoplasm.